Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-sensitive Receptor GPR55

Overview

Journal Mol Endocrinol

Specialties Endocrinology
Molecular Biology

Date 2011 Oct 4

PMID 21964594

Citations 78

Authors

Christopher M Henstridge

Nariman A B Balenga

Julia Kargl

Clara Andradas

Andrew J Brown

Andrew Irving

Cristina Sanchez

Maria Waldhoer

Affiliations

Soon will be listed here.

Abstract

Emerging data suggest that off-target cannabinoid effects may be mediated via novel seven-transmembrane spanning/G protein-coupled receptors. Due to its cannabinoid sensitivity, the G protein-coupled receptor 55 (GPR55) was recently proposed as a candidate; however, GPR55 is phylogenetically distinct from the traditional cannabinoid receptors, and the conflicting pharmacology, signaling, and functional data have prevented its classification as a novel cannabinoid receptor. Indeed, the most consistent and potent agonist to date is the noncannabinoid lysophospholipid, lysophosphatidylinositol. Here we present new human GPR55 mRNA expression data, providing supportive evidence of GPR55 expression in a vast array of tissues and cell types. Moreover, we summarize major recent developments in GPR55 research and aim to update the reader in the rapidly expanding fields of GPR55 pharmacology, physiology, and pathology.

Citing Articles

Utilization of Cannabidiol in Post-Organ-Transplant Care.

Koyama S, Etkins J, Jun J, Miller M, So G, Gisch D Int J Mol Sci. 2025; 26(2).

PMID: 39859413 PMC: 11765766. DOI: 10.3390/ijms26020699.

Analgesic Properties of Next-Generation Modulators of Endocannabinoid Signaling: Leveraging Modern Tools for the Development of Novel Therapeutics.

Singh S, Ellioff K, Bruchas M, Land B, Stella N J Pharmacol Exp Ther. 2024; 391(2):162-173.

PMID: 39060165 PMC: 11493443. DOI: 10.1124/jpet.124.002119.

GPR55 Antagonist CID16020046 Attenuates Obesity-Induced Airway Inflammation by Suppressing Chronic Low-Grade Inflammation in the Lungs.

Son S, Lee Y, Shin Y, Kim D, Im D Int J Mol Sci. 2024; 25(13).

PMID: 39000464 PMC: 11242637. DOI: 10.3390/ijms25137358.

Modulation of neuroinflammation and oxidative stress by targeting GPR55 - new approaches in the treatment of psychiatric disorders.

Apweiler M, Saliba S, Sun L, Streyczek J, Normann C, Hellwig S Mol Psychiatry. 2024; 29(12):3779-3788.

PMID: 38796643 PMC: 11609097. DOI: 10.1038/s41380-024-02614-5.

Elucidation of GPR55-Associated Signaling behind THC and LPI Reducing Effects on Ki67-Immunoreactive Nuclei in Patient-Derived Glioblastoma Cells.

Kolbe M, Hohmann T, Hohmann U, Maronde E, Golbik R, Prell J Cells. 2023; 12(22).

PMID: 37998380 PMC: 10670585. DOI: 10.3390/cells12222646.

References

Bondarenko A, Waldeck-Weiermair M, Naghdi S, Poteser M, Malli R, Graier W . GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol. 2010; 161(2):308-20. PMC: 2931756. DOI: 10.1111/j.1476-5381.2010.00744.x. View

Picone R, Khanolkar A, Xu W, Ayotte L, Thakur G, Hurst D . (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol. 2005; 68(6):1623-35. DOI: 10.1124/mol.105.014407. View

Soria B, Martin F . Cytosolic calcium oscillations and insulin release in pancreatic islets of Langerhans. Diabetes Metab. 1998; 24(1):37-40. View

Caffarel M, Andradas C, Mira E, Perez-Gomez E, Cerutti C, Moreno-Bueno G . Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010; 9:196. PMC: 2917429. DOI: 10.1186/1476-4598-9-196. View

Brown A, Daniels D, Kassim M, Brown S, Haslam C, Terrell V . Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011; 337(1):236-46. DOI: 10.1124/jpet.110.172650. View

Panupinthu N, Lee H, Mills G . Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer. 2010; 102(6):941-6. PMC: 2844037. DOI: 10.1038/sj.bjc.6605588. View

Fonseca B, Correia-da-Silva G, Taylor A, Lam P, Marczylo T, Konje J . N-acylethanolamine levels and expression of their metabolizing enzymes during pregnancy. Endocrinology. 2010; 151(8):3965-74. DOI: 10.1210/en.2009-1424. View

McHugh D, Hu S, Rimmerman N, Juknat A, Vogel Z, Walker J . N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010; 11:44. PMC: 2865488. DOI: 10.1186/1471-2202-11-44. View

Cantarella G, Scollo M, Lempereur L, Saccani-Jotti G, Basile F, Bernardini R . Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol. 2011; 82(4):380-8. DOI: 10.1016/j.bcp.2011.05.004. View

10.

Sawzdargo M, Nguyen T, Lee D, Lynch K, Cheng R, Heng H . Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999; 64(2):193-8. DOI: 10.1016/s0169-328x(98)00277-0. View

11.

Moore D, Murdock P, Watson J, Faull R, Waldvogel H, Szekeres P . GPR105, a novel Gi/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function. Brain Res Mol Brain Res. 2003; 118(1-2):10-23. DOI: 10.1016/s0169-328x(03)00330-9. View

12.

Katona I, Freund T . Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008; 14(9):923-30. DOI: 10.1038/nm.f.1869. View

13.

Zoeller R, Wightman P, Anderson M, Raetz C . Accumulation of lysophosphatidylinositol in RAW 264.7 macrophage tumor cells stimulated by lipid A precursors. J Biol Chem. 1987; 262(35):17212-20. View

14.

Deutsch D, Goligorsky M, Schmid P, Krebsbach R, SCHMID H, Das S . Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997; 100(6):1538-46. PMC: 508335. DOI: 10.1172/JCI119677. View

15.

Bondarenko A, Malli R, Graier W . The GPR55 agonist lysophosphatidylinositol directly activates intermediate-conductance Ca2+ -activated K+ channels. Pflugers Arch. 2011; 462(2):245-55. PMC: 3132407. DOI: 10.1007/s00424-011-0977-7. View

16.

Lappano R, Maggiolini M . G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011; 10(1):47-60. DOI: 10.1038/nrd3320. View

17.

Ford L, Roelofs A, Anavi-Goffer S, Mowat L, Simpson D, Irving A . A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol. 2010; 160(3):762-71. PMC: 2931574. DOI: 10.1111/j.1476-5381.2010.00743.x. View

18.

Maingret F, Patel A, Lesage F, Lazdunski M, Honore E . Lysophospholipids open the two-pore domain mechano-gated K(+) channels TREK-1 and TRAAK. J Biol Chem. 2000; 275(14):10128-33. DOI: 10.1074/jbc.275.14.10128. View

19.

Wang D, Wang H, Ning W, Backlund M, Dey S, DuBois R . Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res. 2008; 68(15):6468-76. PMC: 2561258. DOI: 10.1158/0008-5472.CAN-08-0896. View

20.

Xu Y, Xiao Y, Zhu K, Baudhuin L, Lu J, Hong G . Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord. 2003; 3(1):23-32. View